Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
2023-510486-10-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- May 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of mycophenolate mofetil and tacrolimus in kidney transplant, sponsored by Oslo University Hospital. Primary endpoint: Association between microbiome diversity measures and AUC0-tau and Cmax of mycophenolate and metabolites. Planned start May 2024; status: authorised.
02
Drugs
mycophenolate mofetiltacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2023-510486-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510486-10-00.